Quero Francisco B, Troncoso-Bravo Tays, Farías Mónica A, Kalergis Alexis M
Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Immunotargets Ther. 2025 Apr 28;14:501-514. doi: 10.2147/ITT.S513629. eCollection 2025.
Currently, the management of autoimmune disorders still being a challenge in terms of safety, efficiency, and specificity. Cell-based therapeutic strategies have emerged as a novel approach for autoimmune disease treatment, employing different cell therapy platforms, including tolerogenic dendritic cells, regulatory T cells, conventional and regulatory chimeric antigen receptor-T cells, mesenchymal and hematopoietic stem cells, each with their biological features. Here, we discuss the different cell therapy platforms, their immunological mechanisms of action, their therapeutic potential and benefits in autoimmune diseases, and challenges related to their production, scaling up, risks, and patient safety.
目前，自身免疫性疾病的管理在安全性、有效性和特异性方面仍然是一个挑战。基于细胞的治疗策略已成为一种治疗自身免疫性疾病的新方法，采用了不同的细胞治疗平台，包括耐受性树突状细胞、调节性T细胞、传统和调节性嵌合抗原受体T细胞、间充质干细胞和造血干细胞，每种细胞都有其生物学特性。在此，我们讨论不同的细胞治疗平台、它们的免疫作用机制、在自身免疫性疾病中的治疗潜力和益处，以及与它们的生产、扩大规模、风险和患者安全相关的挑战。
